TOP TEN ANDA / PARA-IV / API OPPORTUNITIES TO BE TARGETED BY GENERIC OR ACTIVE PHARMACEUTICAL INGREDIENT COMPANIES
Product Selection is one of the most crucial aspects of growth strategy for a generic company or an Active Pharmaceutical Ingredient manufacturing company. This 60 page report essentially drills down to 10 drugs, whose volume sales potential are expected to grow manifold, by the time they reach patent expiry and further expand post patent expiry as well. The cumulative sales potential of the drugs discussed in this report exceeds $30b, while due to the impact of therapeutic substitution, post patent expiry should the volume should go up another 50-100%.
The methodology used while selecting the products was.
The product with best in class clinical profile in a particular Therapy area are selected
Out of the 10 products screened, nine have not yet been targeted by Para-IV filer. The products selected span across four therapy areas
The methodology used while selecting the products was.
The product with best in class clinical profile in a particular Therapy area are selected
- Anticipated competition in the therapy and the likelihood of competition scoring over the existing best in class drugs
- Anticipated Clinical studies, which will further strengthen the clinical positioning and help label expansion of the drug within the class
- The impact of therapeutic substitution post patent expiry, which depends on the upcoming competition and the availability of other generic substitutes
Out of the 10 products screened, nine have not yet been targeted by Para-IV filer. The products selected span across four therapy areas
- Cardiovascular
- Cancer
- Central Nervous System
- Metabolic Disorders
COMPANIES MENTIONED
